Additionally, a clinical study involving 761 NSCLC tumors concluded that a significant benefit was associated with the absence of ERCC1, and prolonged survival was observed among patients with low ERCC1 that received cisplatin therapy [8]. This evidence concerns the gene ERCC1 and non-small cell lung carcinoma.